1 In this study, we examined the mechanism(s) by which s.c. nicotine inhibits synovial plasma extravasation. We found that nicotine dose-dependently inhibited bradykinin (BK)-and platelet activating factor (PAF)-induced plasma extravasation. 2 The eect of nicotine on both BK-and PAF-induced plasma extravasation was attenuated by adrenal medullectomy. ICI-118,551 (a selective b 2 -adrenoceptor blocker) (30 mg ml
71, intra-articularly) signi®cantly attenuated the inhibitory action of high-dose (1 mg kg 71 ) nicotine on BK-induced plasma extravasation without aecting the inhibition by low-(0.01 mg kg 71 ) dose nicotine or that on PAFinduced plasma extravasation by nicotine at any dose. This suggested that b 2 -adrenoceptors mediate the inhibitory actions of high-dose, but not low-dose, nicotine. We also found that systemic naloxone (an opioid receptor antagonist) (two hourly injections of 1 mg kg 71 , i.p.) attenuated the inhibitory action produced by all doses of nicotine on BK-or PAF-induced plasma extravasation, suggesting the contribution of endogenous opioids. 3 RU-38,486 (a glucocorticoid receptor antagonist) (30 mg kg 71 , s.c.) and metyrapone (a glucocorticoid synthesis inhibitor) (two hourly injections of 100 mg kg 71 , i.p.) both attenuated the action of high-dose nicotine without aecting that of low-dose nicotine. 4 Spinal mecamylamine (a nicotinic receptor antagonist) (0.025 mg kg
71, intrathecally, i.t.) attenuated the action of high-dose, but not low-dose, nicotine, suggesting that part of the action of high-dose nicotine is mediated by spinal nicotinic receptors. 5 Combined treatment with ICI-118,551, naloxone and RU-38,486 attenuated the action of low-dose nicotine by an amount similar to that produced by naloxone alone but produced signi®cantly greater attenuation of the eect of high-dose nicotine when compared to the action of any of the three antagonists alone.